Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234572 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
A Phase 2 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT00234572 is a Phase 2 study that has completed, run by Ipsen. The registered enrollment target is 108 participants.
The verdict
NCT00234572, a Phase 2 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of lanreotide autogel to placebo after a single injection. Effectiveness and safety were then also assessed following four fixed-dose injections and after one year of treatment given at titrated doses.
Interventions
- DRUG Lanreotide (Autogel formulation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2000-05 |
| Est. Completion | 2003-01-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234572
The ClinicalTrials.gov registry entry for NCT00234572 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lanreotide (Autogel formulation) is the first listed.
NCT00234572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00234572 about?
NCT00234572 is a clinical study titled "Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly". The purpose of this study is to compare the effectiveness of lanreotide autogel to placebo after a single injection. Effectiveness and safety were then also assessed following four fixed-dose injections and after one year of treatment given at titrated doses.
What is the current status of trial NCT00234572?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2000-05. Estimated completion is 2003-01-03.
What interventions are being tested in trial NCT00234572?
The interventions under investigation include: Lanreotide (Autogel formulation) (DRUG).
Who is sponsoring clinical trial NCT00234572?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.